News
Genetic Analysis granted a Canadian patent for companion diagnostic related to IBS treatment with faecal Microbiota Transplant (FMT)
OSLO, NORWAY – 22 September 2026: Genetic Analysis AS (“GA” or “the Company”) announces today that Canadian patent application 3039144…
Genetic Analysis appoints Mira Halvorsen Børstad as Chief Commercial Officer
Appointment strengthens GA’s commercial leadership as GA-map® adoption expands across the USA, Europe, Asia and Australia Oslo, Norway – 3…
Genetic Analysis AS: Publication of Half-year report 2026
OSLO, NORWAY – August 28, 2026: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the half-year report for H1,…
Genetic Analysis Announces First Australian Placement of the GA-map® Dysbiosis Test at Centre for Digestive Diseases in Sydney
Oslo, Norway / Sydney, Australia – 21.08.2026: Genetic Analysis AS (GA), a leader in microbiome diagnostics and developer of the…
Genetic Analysis demonstrates global applicability of the GA-map® Dysbiosis Test in a peer-reviewed publication
OSLO, NORWAY – 16 July 2026: Genetic Analysis AS (“GA” or “the Company”) announces today the publication of a peer-reviewed study…
Publication of interim report January – March 2026
OSLO, NORWAY – May 28, 2026: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the interim report for the…
Minutes of Annual General Meeting
OSLO, NORWAY – 20 May 2026: The Annual General Meeting in Genetic Analysis AS (the “Company”) was held on Wednesday…
Genetic Analysis granted a U.S. patent for companion diagnostic related to IBS treatment response
OSLO, NORWAY – 7 May 2026: Genetic Analysis AS (“GA” or “the Company”) announces today the United States Patent And…
Notice of Annual General Meeting
OSLO, NORWAY – 5 May 2026: Notice is hereby served that the annual general meeting in Genetic Analysis AS (the…
Genetic Analysis AS publishes Annual Report 2025
OSLO, NORWAY – 4 May 2026: Genetic Analysis AS (the “Company”, Ticker: GEAN) hereby publishes the Annual Report for the…
Genetic Analysis to attend DDW congress in Chicago
OSLO, NORWAY, April 30, 2026: Microbiome DX company Genetic Analysis AS (“GA”) announces its attendance at Digestive Disease Week (DDW) congress…
Genetic Analysis AS launches AInsight for AI-assisted interpretation of GA-map® Dysbiosis Test results
OSLO, NORWAY – March 12: Genetic Analysis AS (“GA” or “the Company”) today announces the launch of GA-map® Dysbiosis Test…
Publication of year-end report 2025
OSLO, NORWAY – February 27, 2026: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the year-end report for 2025….
Genetic Analysis AS further strengthens IP portfolio with patent approval in the United States
OSLO, NORWAY – February 19, 2026: Genetic Analysis AS (“GA” or “the Company”) announces that its patent application US2017/0369941 has…
Microbiome Dx Genetic Analysis announces important patent approval enhancing the use of GA-map® in Canada
OSLO, NORWAY – February 12, 2026: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that its important…